PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1983276
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1983276
Skin Rejuvenation Devices Market is estimated to be valued at USD 3,198.70 Mn in 2026 and is expected to reach USD 6,065.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,198.70 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.50% | 2033 Value Projection: | USD 6,065.4 Mn |
Skin rejuvenation involves treating variety of skin disorder such as wrinkles, dark circles, facial lines, pigmentation, scars, stretch marks, acne, dry and itchy skin, and age spots. These skin problems are characterized by the thin and dry skin, loss of skin elasticity, loss of subcutaneous fat tissue, and reduction in production of sebum.
There are various device-based methods of skin rejuvenation such as microdermabrasio, laser-based methods, intense pulsed light photo rejuvenation, sub surfacing non ablative lasers, fractional resurfacing, and radiofrequency devices. These methods can be used alone or in combination, according intensity of the skin problem.
Skin rejuvenation devices offers non-surgical treatment option for curing variety of skin problem mentioned earlier. They provide visible results in minimum time and less need for invasive technique. Increasing awareness about common skin problems, preference to improve visual/ aesthetic appearance, and decreasing device cost is resulting into wide adoption of the skin rejuvenation devices to perform skin rejuvenation related surgeries.
Increasing number of product approval is expected to drive the global skin rejuvenation devices market over the forecast period. For instance, in August 2021, University Medical Center & Dermatology Times editorial advisory board member had cleared the U.S. Food and Drug Administration of Ellacor dermal micro-coring. The Ellacor was recently cleared by the U.S. Food and Drug Administration (FDA) to treat moderate to severe wrinkles in the mid to lower face on Fitzpatrick skin types I through IV. Dr. Michael Abrouk, a cosmetic dermatology fellow at Harvard University who was involved with the Ellacor clinical trials and in January 2022 performs the procedure in practice.
Key features of the study